CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$300.02
−0.04%Oct 15, 2026, 18:30 UTC
CTIBIOTECH and Beijing Vital River signed a memorandum of understanding and strategic partnership to bring CTIBIOTECH’s human tissue bioassays and New Approach Methodologies to China.
Source:Oct 9, 2026, 12:00 UTC
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. announced that it will release third-quarter 2026 earnings and hold a conference call.
Source:Oct 6, 2026, 12:00 UTC
Charles River Laboratories and Autolomous launched Apollo Orchestrate, a new laboratory execution capability built on Autolomous's autoloMATE digital Laboratory Execution System, within Charles River's Apollo platform.
Source:Sep 26, 2026, 01:02 UTC
Charles River Laboratories International unveiled its "Pathway to Purpose" strategic framework and "Create the Future" modernization initiative at its 2026 Investor Day, targeting 5%-7% organic revenue growth, ~24% non-GAAP operating margin, low-double-digit non-GAAP EPS growth through 2030, and at least $300 million in cumulative savings.
Source:Sep 17, 2026, 12:00 UTC
Charles River Laboratories International, Inc. introduced rapid cell banking programs combining rapid cell bank and release packages with Next-Generation Sequencing characterization to accelerate release timelines for biopharmaceutical and advanced therapy developers.
Source:Sep 14, 2026, 14:19 UTC
Charles River Laboratories' stock price extended its decline to 4%.
Source:Sep 14, 2026, 14:13 UTC
Charles River Laboratories' stock fell rapidly by 1.1%.
Source:Aug 11, 2026, 09:30 UTC
Charles River Laboratories International's stock reached a new 52-week high on Tuesday, trading as high as $277.07.
Source:Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. repurchased $100 million of its common stock during the second quarter of 2026 at an average price of $174 per share.
Aug 5, 2026, 00:00 UTC
Charles River Laboratories International, Inc. reported its second quarter 2026 financial results, with total revenue of $1.00 billion, a GAAP net loss of $1.5 million, and non-GAAP diluted EPS of $3.02.
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jul 13, 2026, 12:00 UTC
Charles River Laboratories announced a collaboration with Arovella Therapeutics to provide GMP NGS services for cell characterization, supporting Arovella's iNKT cell therapy platform for cancer treatment.
Jun 25, 2026, 05:00 UTC
Eli Lilly started a collaboration with about 100 smaller biotechs, including Charles River Laboratories, to work with AI models in return for their data.
Source: